Comparative sensitivity study of primary cells, vero, OA3.Ts and ESH-L cell lines to lumpy skin disease, sheeppox, and goatpox viruses detection and growth

Rhazi, Halima; Safini, Najete; Mikou, Karima; Alhyane, Meryeme; Lenk, Matthias; Tadlaoui, Khalid Omari; Elharrak, Mehdi

doi:10.1016/j.jviromet.2021.114164

Cited by 19 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The host range is slightly broader in cell culture of LSDV. A number of primary cell types derived from lamb and bovine tissue enable the growth of LSDV to high titres and are commonly used for vaccine stock preparations [ 18 , 19 ]. LSDV also grows well in chick chorioallantoic membranes (CAMs) of embryonated eggs, although purification of the virus may need to be extensive which can cause a loss in yields [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lumpy Skin Disease—An Emerging Cattle Disease in Europe and Asia

2023

View full text Add to dashboard Cite

Lumpy skin disease virus (LSDV) is a member of the Capripoxvirus genus, mainly infecting cattle and buffalo, which until relatively recently was only endemic in parts of Africa and then spread to the Middle East and lately Europe and Asia. Lumpy skin disease (LSD) is a notifiable disease with a serious impact on the beef industry as it causes mortality of up to 10% and has impacts on milk and meat production, as well as fertility. The close serological relationship between LSDV, goat poxvirus (GTPV) and sheep poxvirus (SPPV) has led to live attenuated GTPV and SPPV vaccines being used to protect against LSD in some countries. There is evidence that the SPPV vaccine does not protect from LSD as well as the GTPV and LSDV vaccines. One of the LSD vaccines used in Eastern Europe was found to be a combination of different Capripoxviruses, and a series of recombination events in the manufacturing process resulted in cattle being vaccinated with a range of recombinant LSDVs resulting in virulent LSDV which spread throughout Asia. It is likely that LSD will become endemic throughout Asia as it will be very challenging to control the spread of the virus without widespread vaccination.

show abstract

Section: Introductionmentioning

confidence: 99%

“…A recently developed embryonic skin of sheep (ESH-L) cell line was also shown to yield high titres of LSDV [ 19 ]. LSDV also replicates in Vero (African green monkey kidney) cells and the ovine testis (OA3.Ts) cell line [ 18 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Lumpy Skin Disease—An Emerging Cattle Disease in Europe and Asia

2023

View full text Add to dashboard Cite

show abstract

“…MDBK and Vero cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Primary cattle testicle (PCT) cells were isolated (Rhazi et al., 2021) from testicle tissue of 16‐week‐old healthy cattle (no specific pathogen) as previously described and maintained in RPMI‐1640 medium containing 10% FBS, HyClone), 100 U/ml penicillin, 50 mg/ml streptomycin and nonessential amino acids (NEAAs, Gibco). All cells were cultured at 37℃ with 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

Isolation, identification and phylogenetic analysis of lumpy skin disease virus strain of outbreak in Guangdong, China

Wang

et al. 2022

Transbounding Emerging Dis

View full text Add to dashboard Cite

In August 2019, lumpy skin disease occurred for the first time in Xinjiang, China, and then quickly spread to many provinces in China. Here, the virus was isolated from the skin scabs of affected cattle during June 2020 in Guangdong, China. Virus isolation, transmission electron microscopy and polymerase chain reaction identified lumpy skin disease virus (LSDV) in the skin crusts of sick cattle. For the isolation of LSDV, the most sensitive cell line is primary cattle testicular (PCT) cells, while Vero cells cannot be used for the isolation of LSDV. In addition, we evaluated the growth characteristics of LSDV in vitro. Compared with MDBK and Vero cells, LSDV produced higher virus titters in PCT cells at 72 h. Phylogenetic analysis based on second-generation sequencing of the LSDV whole genome showed that the isolated virus (LSDV/MZGD/2020) is closely related to Asian strains and formed a new branch. LSDV/MZGD/2020 is also a vaccine recombinant strain that is distinct from the recombinant strain found in Russia. Through Recombination Detection Program (RDP), Simplot and phylogenetic analyses, strong evidence for recombination events was found in Chinese field LSDV strains. The China LSDV/MZGD/2020 strain may be the result of multiple recombination events between the Neethling 2490 and Neethling vaccine LW 1959 strains. This study expands our knowledge of the genetic diversity and evolution of LSDV.

show abstract

“…The promising immune responses to LSDV in replication-restricted hosts have supported the development of LSDV as a vaccine for humans [ 19 , 20 ]. However, the present manufacture of vaccines takes place in cell lines or primary cultures [ 21 , 22 ], which are not suitable for the manufacturing of human vaccines according to current good manufacturing practice. Madin–Darby bovine kidney (MDBK) cells can be used for culture in veterinary use, but this cell line is often contaminated with bovine viral diarrhea virus (BVDV).…”

Section: Introductionmentioning

confidence: 99%

“…Passaging through embryonated chicken eggs can be used to remove this BVDV [ 23 ], but eggs are not considered a viable alternative for manufacture of vaccine. Recently, it was reported that Capripoxviruses grow well in cultures of the embryonic skin of sheep (ESH-L) and primary foetal heart cells, but to a lesser extent in Vero cells and an ovine testis cell line [ 21 ]. One of the aims of our study was to determine if the manufacture of LSDV could be done in a baby hamster kidney cell line (BHK-21), which is suitable for vaccine manufacture for human vaccines.…”

Section: Introductionmentioning

confidence: 99%

Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector

et al. 2021

View full text Add to dashboard Cite

Attenuated vaccine strains of lumpy skin disease virus (LSDV) have become increasingly popular as recombinant vaccine vectors, to target both LSDV, as well as other pathogens, including human infectious agents. Historically, these vaccine strains and recombinants were generated in primary (lamb) testis (LT) cells, Madin–Darby bovine kidney (MDBK) cells or in eggs. Growth in eggs is a laborious process, the use of primary cells has the potential to introduce pathogens and MDBK cells are known to harbor bovine viral diarrhea virus (BVDV). In this study, data is presented to show the growth of an attenuated LSDV strain in baby hamster kidney (BHK-21) cells. Subsequently, a recombinant LSDV vaccine was generated in BHK-21 cells. Partial growth was also observed in rabbit kidney cells (RK13), but only when the vaccinia virus host range gene K1L was expressed. Despite the limited growth, the expression of K1L was enough to serve as a positive selection marker for the generation of recombinant LSDV vaccines in RK13 cells. The simplification of generating (recombinant) LSDV vaccines shown here should increase the interest for this platform for future livestock vaccine development and, with BHK-21 cells approved for current good manufacturing practice, this can be expanded to human vaccines as well.

show abstract

Comparative sensitivity study of primary cells, vero, OA3.Ts and ESH-L cell lines to lumpy skin disease, sheeppox, and goatpox viruses detection and growth

Cited by 19 publications

References 12 publications

Lumpy Skin Disease—An Emerging Cattle Disease in Europe and Asia

Lumpy Skin Disease—An Emerging Cattle Disease in Europe and Asia

Isolation, identification and phylogenetic analysis of lumpy skin disease virus strain of outbreak in Guangdong, China

Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector

Contact Info

Product

Resources

About